Immvention & Novo Nordisk Unite
IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions.
The partnership will leverage IMMvention’s investigational small-molecule BACH1 inhibitors. BACH1 is thought to be a key regulator of cellular responses, oxidative stress, and inflammation in multiple disease states, making it a promising therapeutic target. Currently in preclinical development, IMMvention’s orally dosed BACH1 inhibitors have the potential to increase fetal hemoglobin, which is believed to ameliorate SCD disease pathology. Under the agreement, Novo Nordisk will gain an exclusive worldwide license to IMMvention’s BACH1 program. The companies will work together closely to advance BACH1 inhibitors from the program to development candidate nomination. Upon or prior to nomination of a development candidate, Novo Nordisk will take over all further development, regulatory submissions, and commercialization worldwide.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins